Dyne Therapeutics (DYN) Payables (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Payables data on file, last reported at $10.8 million in Q1 2026.

• On a quarterly basis, Payables rose 53.6% year-over-year to $10.8 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 53.6% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 23.16% from the prior year.
• Payables for Q1 2026 stood at $10.8 million, up from $8.1 million in the prior quarter.
• Over the last five years, Payables for DYN reached as high as $22.9 million in Q4 2023 and fell as low as $919000.0 in Q3 2022.
• Historically, Payables has averaged $7.7 million across 5 years, with a median of $7.0 million in 2022.
• Across the five-year window, Payables slumped 87.03% in 2022 and jumped 641.98% in 2025, its largest moves.
• Year by year, Payables stood at $5.3 million in 2022, then surged by 336.13% to $22.9 million in 2023, then tumbled by 71.39% to $6.6 million in 2024, then advanced by 23.16% to $8.1 million in 2025, then jumped by 33.4% to $10.8 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $10.8 million in Q1 2026, $8.1 million in Q4 2025, and $12.1 million in Q3 2025.